title: Adjuvant systemic therapy protocol for Dukes' B2 and C resectable colon carcinoma.
abstract: OBJECTIVE
  Trials of adjuvant systemic therapy in high risk patients with Dukes' B2 and C colon cancer utilizing 5-fluorouracil-based regimens have been ongoing since the 1960s. The aim of this study was to compare the combination of 5-FU and leucovorin with the combination of 5-FU and alfa-2b interferon (IFN) in patients who had undergone "curative" resection foronocarcinoma.
  
  
  METHODS
  A total of 322 patients with histologically proven adenocarcinoma of the colon, Dukes' stage B2 and C, were entered in the study. They were randomized to A) leucovorin 20 mg/m2 rapid intravenous injection and 5-FU 425 mg/m2 IV days 1-5 every 28 days for six cycles or B) 5-FU 600 mg/m2 24-hour infusion for five days, then 600 mg/m2 IV once a week and IFN 5 MU subcutaneously three times a week for six months.
  
  
  RESULTS
  There was no statistically significant difference in either disease-free survival or overall survival. Toxicity was the same in the two groups with the exception of flu-like syndrome, which was universal in IFN-treated patients.
  
  
  CONCLUSIONS
  There was no difference in disease-free survival or overall survival between the two combinations in any patient subset. Toxicity was greater with the 5-FU+IFN combination because of the flu-like syndrome. These data do not support the use of IFN in combination with 5-FU as systemic adjuvant therapy for patients with locally advanced colon carcinoma.
authors: Second Department of Surgery, Areteion Hospital, University of Athens, Greece. gennatas@compulink.gr
authors: Constantine
authors: C
authors: Gennatas
authors: Despoina
authors: D
authors: Mouratidou
authors: George
authors: G
authors: Androulakis
authors: Vasilios
authors: V
authors: Georgoulias
authors: Nikolaos
authors: N
authors: Tsavaris
authors: Michail
authors: M
authors: Philippakis
authors: Emmanouil
authors: E
authors: Michailakis
authors: Charalampos
authors: C
authors: Kalofonos
authors: Stavros
authors: S
authors: Mpesmpeas
authors: John
authors: J
authors: Katsos
authors: Miranda
authors: M
authors: Tsitoura
authors: George
authors: G
authors: Retalis
authors: Elias
authors: E
authors: Mallas
authors: Dionysios
authors: D
authors: Voros
authors: Charalampos
authors: C
authors: Andreadis
authors: George
authors: G
authors: Hatzistylianos
authors: Christos
authors: C
authors: Pisiotis
authors: Dimitrios
authors: D
authors: Kamilarios
authors: Sotirios
authors: S
authors: Kakoliris
authors: Vasilios
authors: V
authors: Komporozos
authors: Dimitrios
authors: D
authors: Kannas
authors: Nikolaos
authors: N
authors: Legakis
authors: Theodoros
authors: T
authors: Mpatakis
authors: John
authors: J
authors: Ntamtsios
authors: Evangelos
authors: E
authors: Papaevangelou
authors: George
authors: G
authors: Peros
authors: Alexis
authors: A
authors: Photopoulos
authors: Anastasia
authors: A
authors: Pouli
authors: Sotirios
authors: S
authors: Prigouris
authors: Lazaros
authors: L
authors: Samanidis
authors: Vasilios
authors: V
authors: Sakellariou
authors: Vasilios
authors: V
authors: Smyrniotis
authors: George
authors: G
authors: Polymeneas
authors: John
authors: J
authors: Vasiliou
authors: Athanasios
authors: A
authors: Athanasiou
authors: John
authors: J
authors: Papadimitriou
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D018572:Disease-Free Survival; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage; D002955:Leucovorin / Q000008:administration & dosage; D008297:Male; D009367:Neoplasm Staging; D011994:Recombinant Proteins; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D002955:Leucovorin; D005472:Fluorouracil